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Abstract The study aims to describe patient characteristics,
uterine cavity shape and histopathology, complications, and
long-term clinical outcomes of women who failed hysteroscopic rollerball or loop endometrial ablation (HEA) and
subsequently consented to repeat hysteroscopic endometrial
ablation (RHEA), and is a retrospective cohort study (Canadian Task Force classification II-2). The study was conducted
in the university-affiliated teaching hospital. Patients included women who failed primary hysteroscopic endometrial ablation (PHEA, n=183) and subsequently underwent RHEA
by the senior author (GAV) from 1993 through 2007 with a
minimum follow-up of 5 years. RHEA was performed under
general anesthesia using 26 F (~9 mm) resectoscope,
monopolar loop electrode in 136 (74.3 %), 3–5 mm rollerball
in 41 (22.4 %) or combination in 6 (3.3 %) women. Patient
characteristics, uterine cavity, and clinical outcomes of women who failed PHEA and subsequently consented to RHEA
were evaluated by retrospective chart review and patient
follow-up including office visits and/or telephone interview.
The corresponding median age (range) for PHEA and RHEA
was 40 (26–70) and 43 (29–76) years. Indications for PHEA
included abnormal uterine bleeding (AUB, 52.7 %), AUB
and dysmenorrhea (25.8 %), dysmenorrhea (18.8 %), and
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others (2.7 %). Indications for RHEA included persistent
AUB (53 %), AUB and uterine/pelvic pain (26.2 %),
uterine/pelvic pain only (19.1 %), postmenopausal bleeding
(1.1 %), and thickened endometrium (0.5 %). Complications
of RHEA (n=7, 3.8 %) included false passage (3), uterine
perforation (2), and bleeding (2). One patient with excessive
bleeding required immediate hysterectomy. At a median
follow-up of 9 years (5–19), 69 % of women avoided hysterectomy. Repeat hysteroscopic endometrial ablation is a
feasible, safe, and long-term effective alternative to hysterectomy for abnormal uterine bleeding from benign causes
when performed by experienced surgeons.
Keywords Abnormal uterine bleeding . Heavy menstrual
bleeding . Menorrhagia . Hysteroscopic endometrial ablation .
Repeat endometrial ablation

Introduction
First-generation endometrial ablation techniques performed
by hysteroscopic endometrial ablation (HEA) were introduced
in the 1980s as an alternative to hysterectomy to treat women
with abnormal uterine bleeding (AUB) from benign causes.
These included endometrial laser ablation and radiofrequency
rollerball/bar or transcervical resection of the endometrium
(TCRE) [1, 2]. Second-generation endometrial ablation technologies, also referred to as global endometrial ablation
(GEA) or nonhysteroscopic endometrial ablation, were introduced in the 1990s as Bautomated,^ easier, and safer alternatives to hysteroscopic endometrial ablation requiring less skill
and could be performed in the office [3, 4].
Following endometrial ablation by any technique and technology, including hysteroscopic endometrial ablation (HEA),
long-term outcomes (within 10 years) indicate that 15 to 30 %
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of women require additional surgery such as hysterectomy for
persistent AUB, uterine/pelvic pain, or both [5–7]. The subsequent 30 % hysterectomy rate after endometrial ablation
together with a high satisfaction rate of women who chose
hysterectomy as primary treatment of their AUB [7] has raised
some serious issues, questions, and concerns regarding the
cost-effectiveness, ongoing utilization, and indeed the future
of both hysteroscopic and nonhysteroscopic endometrial ablation for the treatment of AUB.
Consequently, many gynecologists resort to hysterectomy
for both as primary treatment of AUB and as the next logical
step in women who fail primary endometrial ablation. However, in spite of major technological advances in minimally
invasive gynecological surgery, hysterectomy remains a major
surgical procedure associated with significant morbidity, mortality, and health care costs and resources [7–11].
To minimize the post-ablation hysterectomy rate, a few
gynecological surgeons have reported their experience with
repeat hysteroscopic endometrial ablation (RHEA) using the
resectoscope with [12] or without concomitant utilization of
ultrasonic guidance [13–16]. Based on these reports, RHEA
appears to be more challenging to perform and may be associated with a higher complication rate [16].
For the above reasons, in our center, we have developed a
relatively easy and safe technique and we routinely offer
RHEA as an alternative to hysterectomy when primary HEA
[17] and non-HEA [18] fail and patients continue to complain
of persistent AUB, uterine/pelvic pain, or both.
In the present study, we describe our technique and experience, as well as patient characteristics, indications, and
long-term outcomes in women who failed hysteroscopic
rollerball or loop endometrial ablation and subsequently
consented to RHEA.

Materials and methods
From 1990 through December of 2007, the senior author
(GAV) performed 3768 primary HEA using 3–5-mm
rollerball electrodes, 8-mm cutting loop electrodes, or a
combination of the two to treat women with AUB. In addition, 183 women who had failed primary HEA underwent
RHEA by the same surgeon from January 1991 through
December 2007. We are aware that some of our patients
who failed primary HEA received various treatments, including repeat ablation and/or hysterectomy, by other gynecologists in the area. Therefore, 183 of 3768 cases represent
a minimal rate of approximately 5 % repeat ablations among
our initial population.
All women who presented with persistent AUB and/or
uterine/pelvic pain after primary HEA had complete assessment including pelvic examination and imaging using abdominal and transvaginal ultrasound and/or MRI when indicated.
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Endometrial biopsy was attempted in all women with uterine bleeding but, in the majority of cases, we were unable to
access the uterine cavity or obtain an adequate/satisfactory
sample in the clinic. For this reason, women with postmenopausal bleeding were also included if the endometrial cavity
and endometrium could not be assessed in the office. Consequently, we performed endometrial resection in the majority of
cases or D&C and we always obtained an endometrial sample
in the operating room during RHEA.
Patients were offered several treatment options including
medical therapy in the presence of adequate and normal endometrial histopathology especially if they were nearing menopause, RHEA, or hysterectomy. When RHEA was chosen,
patients were counseled appropriately and informed consent
was obtained. None of the patients undergoing RHEA was
pretreated to thin the endometrium.
After general anesthesia, with the patient in appropriate
stirrups and horizontal dorsolithotomy position, a bimanual
pelvic examination was performed to assess the size, shape,
mobility, and, most importantly, the position of the uterus.
None of the RHEA was performed under ultrasonic or laparoscopic guidance although 30 (17 %) women underwent concomitant laparoscopy for a variety of additional indications
including pelvic pain and/or pelvic mass.
Technique of repeat hysteroscopic endometrial ablation
Following bimanual pelvic examination, the anterior lip of
the cervix was grasped with a double-toothed tenaculum and
the cervical canal was gradually dilated up to the level of the
internal os (approximately 4 cm) using Hagar dilators. Occasionally, a single-toothed tenaculum was applied to the posterior lip of the cervix to redistribute the tension between the
anterior and posterior lip of the cervix to minimize the risk of
cervical tears and maintain the cervical canal straight. If resistance was encountered with any of the dilators, a 5-mm hysteroscope was used to visualize the cervical canal and internal
os. Bearing in mind the length and direction of the cervical
canal and the position of the uterus, the cervical canal was
subsequently dilated to 10 mm.
The resectoscope was introduced, and the endocervical canal was superficially resected to facilitate inflow and outflow
of the distending/irrigant solution and visualize better the
utero-isthmic junction and any residual uterine cavity. Up to
the year 2000, if a uterine cavity was present, we used mostly
a 3-mm rollerball electrode to ablate any visible endometrium
and or endometrial pockets. In the absence of a recognizable
uterine cavity or in the presence of narrow distorted cavities,
the endometrial/endouterine cavity was resected taking small
cuts with the loop electrode by alternating sides following any
residual endometrial canal until the entire cavity was recreated
and all visible endometrial remnants were resected (Fig. 1).
After we analyzed the results of using rollerball ablation
versus loop resection for RHEA, we noticed that the rate of
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Fig. 1 Clockwise sequence of repeat hysteroscopic endometrial
resection with the loop electrode

failed RHEA that underwent hysterectomy was 36.6 % for
rollerball compared with 23.2 % for resection. In addition,
we found that it was easier and safer to resect rather than
rollerball the residual endometrial cavity. For this reason,
around the year 2000, we started doing more RHEA using
resection with the loop electrode rather than ablate with the
rollerball (Fig. 2).
In the majority of RHEA, the uterus was distended using
1.5 % glycine solution via an automated fluid management
system (Endomat; Karl Storz GmbH & Co., Tuttlingen, Germany) set at an infusion rate of 300 mL/min, pump pressure of
80 mmHg, and suction at 0.2 bar. Prior to the availability of
this system, from the year 1990 to 2000, a gravity system was
used, at 100 cmH2O (~75 mmHg) infusion pressure with 80–
100 mmHg wall suction, to evacuate smoke bubbles, clots,
and debris from the uterus. We used a 26 F (9 mm diameter)
monopolar resectoscope (Karl Storz GmbH & Co., Tuttlingen,
Germany) with an 8-mm monopolar loop electrode at 120 W
Fig. 2 Type of repeat
hysteroscopic endometrial
ablation versus calendar year
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of low voltage continuous (cut) waveform in 136 women
(74.3 %), rollerball with high voltage interrupted (coag) waveform in 41 women (22.4 %), and a combination of the two in 6
women (3.3 %). Rollerball ablation was allowed if an endometrial cavity was reasonably well preserved. Time required
to perform a RHEA is not different than that of primary HEA;
approximately 15 min.
After the university ethics board approval (HSRB 13849E),
we retrospectively identified and reviewed the medical records
of these women and follow-up was conducted through office
visits and/or telephone interviews. Exclusion criteria included
patients who did not have a minimum follow-up of 5 years
since their RHEA or did not wish to participate in the study.
Data collected included patient characteristics such as age,
body mass index (BMI), parity, and obstetrical history (i.e.,
cesarean section, vaginal deliveries) at the time of primary
HEA, type of primary ablation (i.e., rollerball, resection, or
both) and indications for primary and RHEA. In addition,
we recorded uterine cavity findings and appearance, laparoscopic findings and procedures performed at time of RHEA
for women who underwent concomitant laparoscopy, and any
complications encountered during all procedures.
Follow-up data included outcome of RHEA (i.e., requirement for additional treatment such as any medical therapy, third
repeat ablation, or hysterectomy), patient satisfaction, and
avoidance of hysterectomy. In those women who required no
further treatment after RHEA, their menstrual blood loss was
classified as amenorrhea, spotting, hypomenorrhea, and persistent AUB, taking into account their age and menopausal status.
Medical records were reviewed, and telephone interviews
were conducted to determine if hysterectomy was performed
by a different surgeon than the surgeon who performed the
RHEA. If hysterectomy was performed, efforts were made to
collect data including date, indication, and histopathology of
the hysterectomy specimen.

318

Data were analyzed using SAS software (SAS Institute,
Inc., Cary, NC). The median and range are used to describe
non-normal data, and the mean (SD) and 95 % confidence
interval are used to describe normal distribution variables. A
p value <0.05 was considered statistically significant.

Results
An algorithmic summary of the 183 women who underwent
repeat HEA is provided in Fig. 3. Twenty-five (13.6 %) women
were lost to follow-up. Of the remaining 158 (86.3 %) women
with a median follow-up of 9 years (range 5–19), 102 (64.6 %)
required no further treatment. Two women (1.3 %) were deceased from etiologies unrelated to RHEA, one from cervical
cancer and the other from disseminated breast cancer.
The patient with cervical cancer had RHEA 6 months after
HEA. Following 5 years of amenorrhea, she developed irregular vaginal bleeding and cervical biopsy indicated invasive
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squamous cell carcinoma, moderately differentiated (stage II
b). She died of her disease 1 year after radical surgery.
The patient with breast cancer had RHEA 2 years after
HEA. Ten years later, she was diagnosed with breast cancer
and died of her disease 6 years after therapy.
Fifty-six women (35.4 %) required further treatment including hysterectomy (n =49, 31.0 %), third HEA (n=3,
1.9 %), or short-term medical therapy (n=4, 2.5 %).
The interval from primary to repeat HEA is shown in Fig. 4
indicating that the majority (72.1 %) of RHEA were performed within the first 3 years of the primary HEA.
The demographics and characteristics of the women who
received RHEA including body mass index (BMI), parity, and
mode of delivery are shown in Table 1 while the indications
for both are shown in Table 2. Persistent bleeding was the
most common indication for both primary and RHEA.
Uterine cavity appearance and findings at RHEA The cavity appearance was described as contracted (n=56, 35.4 %), containing endometrial pockets (n=25, 15.8 %), and septum-like

Fig. 3 Algorithmic summary of all patients who had repeat hysteroscopic endometrial ablation (HEA)
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Fig. 4 Interval in years to repeat
hysteroscopic endometrial
ablation

(n=4, 2.5 %). The cavity was described as normal in six cases
(3.8 %) and absent in seven cases (4.4 %). The cavity was not
described in 60 cases (38.0 %). Findings included leiomyoma
(n=17, 10.7 %), hematometra (n=14, 8.9 %), and polyp (n=1,
0.6 %). No specific lesions were described in 126 cases (80.0 %).
From 1991 through 1999, repeat HEA (n=49) was performed by rollerball (n = 33, 67.3 %), resection (n = 11,
22.4 %), and combined (n=5, 10.2 %). From the year 2000
and thereafter, RHEA (n=134) was performed by resection
(n=125, 93.3 %), rollerball (n=8, 6.0 %), or combination of
the two (n=1, 0.7 %) (Fig. 2).
Findings and procedures at concomitant laparoscopy At
RHEA, 30 women had concomitant laparoscopy for pain and/
or pelvic mass. Laparoscopic findings included endometriosis
in 24, adhesions in 10, and hematosalpinx in 3 women. Laparoscopic procedures included excision of endometriosis and
adhesiolysis, and bilateral salpingectomy in 15, salpingooophorectomy in 6, and appendectomy in 1 woman. Of these
30 women, 13 (43.3 %) underwent hysterectomy at a later
date for pain (n = 9), pain and bleeding (n = 3), and
hematometra (n=1). Hysterectomy was performed vaginally
in 6, LAVH in 3, and abdominally in 4 women.
Perioperative complications of RHEA Among the 183
RHEA, complications were encountered in 7 women
(3.8 %) including uterine perforation (n=2), creation of false
passage (n=3), and excessive bleeding (n=2).
Table 1 Demographics and type
of endometrial ablation of 183
women who underwent RHEA
(%)

Uterine perforation with the resectoscope was encountered in two cases. One case resulted in incomplete resection
and laparoscopy identified no intra-abdominal injury. This
patient subsequently underwent vaginal hysterectomy for
pain. Histopathology of the uterine specimen identified
leiomyoma. The second case of uterine perforation did have
a complete endometrial resection; however, the patient
underwent abdominal hysterectomy in a peripheral hospital
within a week of the RHEA for infection. There was no
intra-abdominal injury noted. Histopathology of the uterine
specimen was not available.
Sub-endometrial false passage was created in three cases
all of which had complete resections. One patient was lost to
follow-up while the other two subsequently had vaginal hysterectomy and abdominal hysterectomy for pain. Histopathology demonstrated normal tissue in the first and adenomyosis
in the second case.
Two cases of RHEA resulted in excessive intraoperative
bleeding. In one case, the bleeding was resolved by
tamponade with a Foley catheter balloon. The second case
resulted in emergency vaginal hysterectomy and adenomyosis
and leiomyoma were found on histopathology.
Incomplete RHEA was performed in one patient who was
morbidly obese and was lost to follow-up.

Outcomes after RHEA Of the 158 women who were followed for a minimum of 5 years, 102 (64.6 %) required no further
treatment while 49 (31.0 %) had hysterectomy, 3 (1.9 %)

Age (years), median (range)
Body mass index (kg/m2), median (range)
Parity
Nulliparous
Parous
Mode of delivery
Cesarean section
Vaginal delivery
Type of ablation
Rollerball
Resection
Combined

Primary ablation

Repeat ablation

40 (26–70)
25.1 (17.7–61.2)
19 (10.4)
164 (89.6)
34 (18.6)
130 (71.0)
87 (47.5)
62 (33.9)
34 (18.6)

43 (29–76)

41 (22.4)
136 (74.3)
6 (3.3)
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Table 2 Indications for primary and repeat hysteroscopic endometrial
ablation (N=183)
Indication

Primary

Repeat

AUB (1 with simple hyperplasia)

159 (86.9 %)

97 (53.0 %)

AUB+dysmenorrhea/pain

19 (10.4 %)

48 (26.2 %)

Dysmenorrhea/pain
PMB (undiagnosed)

2 (1.1 %)
3 (1.6 %)

35 (19.1 %)
2 (1.1 %)

Thickened endometrium

-

1 (0.5 %)

Total

183 (100 %)

183 (100 %)

underwent third HEA, and 4 (2.5 %) were administered shortterm medical therapy including oral contraceptives (n=2,
1.3 %), danazol (n=1, 0.6 %, Sanofi-Aventis Canada Inc.,
Laval, QC, Canada), and depo-medroxyprogesterone acetate
(DMPA, n=1, 0.6 %) (Fig. 3).
Indications for hysterectomy The most common indication
for hysterectomy after RHEA was pelvic pain (n=22, 44.9 %)
followed by pelvic pain and bleeding (n=17, 34.7 %), and
bleeding alone (n=4, 8.2 %). Six women (12.2 %) had hysterectomy with or without salpingo-oophorectomy for other
indications including uterine prolapse (n = 1, 2.0 %),
leiomyoma (n=3, 6.1 %), breast cancer (n=1, 2.0 %), and
uterine perforation and sepsis (n=1, 2.0 %).
Type of hysterectomy The most common type of hysterectomy performed was vaginal (n=24, 49 %), followed by total
abdominal (n=18, 36.7 %) and laparoscopic-assisted vaginal
hysterectomy (LAVH, n=6, 12.2 %). One (2.0 %) hysterectomy was not performed by the senior author (GAV), and thus,
the type of hysterectomy and histopathology was unknown as
hospital records were not accessible.
Histopathology of hysterectomy specimens The most common histopathology of hysterectomy specimens after RHEA
was adenomyosis (n=18, 37.0 %) followed by no specific
pathology (n=14, 28.6 %), and leiomyoma (n=12, 24.5 %).
Two specimens (4.1 %) included endometriosis and one specimen included simple endometrial hyperplasia without atypia
(2.0 %). Four (8.2 %) histopathology results are unknown.

Discussion
Review of the available literature on long-term clinical outcomes of endometrial ablation for the treatment of AUB raises
several observations, questions, and concerns.
One observation is that both HEA and non-HEA, by any
technique or technology, appear to be of diminishing effectiveness with time [5–7]. As presented in the BIntroduction,^ it

is becoming more evident that within the first 10 years of
endometrial ablation, up to 30 % of women end up with a
hysterectomy for a variety of reasons mostly related to the
original problem of AUB and/or pain.
Since the median age of women undergoing endometrial
ablation is in their early 40s and 30 % of them require hysterectomy within the next 10 years to resolve their original problem of AUB/dysmenorrhea, it stands to reason that at least an
additional 10 % of women will require hysterectomy for other
indications including uterine neoplasia, pain, prolapse, etc.,
during their lifetime. If one accepts this reasoning with a hysterectomy rate exceeding 30 % after endometrial ablation, then
endometrial ablation may no longer be cost-effective [19]..
For these reasons, if one is to preserve endometrial ablation in everyday clinical practice, strategies must be developed to improve its feasibility and increase its safety and
long-term efficacy.
One strategy to maintain utilization of endometrial ablation
and minimize hysterectomy may be a wider utilization of repeat endometrial ablation. As stated in the BIntroduction,^
several authors have reported their experience with RHEA
after failed HEA [12–16] and non-HEA [18, 20]. However,
since the literature on repeat ablations is very scanty, it is
reasonable to assume that this is not a very appealing and
widely practiced option. This lack of appeal may be related
to a number of reasons including the lack of surgical experience and expertise, increased complications, the absence of
evidence-based long-term efficacy, and the ease of solving
the problem definitively with a simple hysterectomy.
As stated above, from 1991 through 1999, RHEA in our
center was performed mostly by rollerball (67 %) while from
around the year 2000 to the present, RHEA is performed
mostly by resection (93 %). We have found that the use of
the loop electrode under direct vision is safer and more efficacious than the rollerball as shown by reduced rates of complications and hysterectomy in the present study and that of
Istre and Langebrekke [14] using a similar technique to ours.
On the other hand, Wortman and Daggett [12, 20] advocate
the use of concomitant ultrasonic guidance during RHEA.
This additional feature however, although conferring an element of safety, requires additional utilization of ultrasound
equipment and personnel in the operating room.
We have previously reported higher complications associated with RHEA (OR 4.01, 95 % CI 1.63–9.87) than primary
HEA. However, those numbers may reflect lack of experience
at that time and the different technique we used prior to the
year 2000. In our previous study, the overall complication rate
for RHEA was 9.30 % (7 cases out of 75) versus 2.05 % (20
cases out of 800) for RHEA (p=0.006) [16].
In the present study, the overall complication rate with
RHEA was 3.8 %. The present complications are similar to
those reported by others, with one study reporting two uterine
and one cervical perforations (4.5 %). The three women with
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perforation were operated by less-experienced endoscopic
surgeons [15]. The three other studies reported no complications [12–14]. This indicates that RHEA may be a relatively
safe procedure when performed by experienced surgeons.
Although RHEA has been reported to be feasible and relatively safe, feasibility is not an indication unless it is shown
to be effective. In our study, following RHEA, 69 % of women avoided hysterectomy including 17/158 (10.8 %) women
who had undergone concomitant laparoscopy This rate is
within the range of 54 to 100 % within 5 years of follow-up
reported by others [12–15]. Whether this rate is significant
enough to justify repeat ablation as an alternative to hysterectomy or bypass it all together and go directly to a vaginal or
laparoscopic hysterectomy cannot be answered at this time.
In the present study, indications for repeat ablation were
persistent AUB (53 %), uterine/pelvic pain (19 %), or both
AUB and pain (26 %) while the most common indication for
hysterectomy after RHEA was pelvic pain (45 %) followed by
pelvic pain and bleeding (35 %). Similar results have been
reported by others reporting 33 (28 %) of RHEA receiving
hysterectomy for pain (48 %), persistent bleeding (27 %), and
pain and bleeding (10 %) [14]. It is of interest to note that all
authors report that hysterectomy was performed at a median of
approximately 3 years after RHEA [12, 14, 15].
Pelvic pain after endometrial ablation has been attributed to
several conditions including adenomyosis, hematometra,
post-ablation tubal sterilization syndrome (PATSS), endometriosis, and others [21–23]. Indeed, in our study, the most
common histopathology of hysterectomy specimens after
RHEA was adenomyosis (37 %). Adenomyosis in hysterectomy specimen was reported from 58 to 61 % in three other
studies [12, 14, 15].
The low rate of hematometra (n=14, 8.9 %) and PATSS
(n = 3) may be related to our technique of meticulous
electrocoagulation or complete resection of the tubal cornua
as described previously [24]. Sterilization by tubal occlusion
has been identified as a predictor of pain after endometrial
ablation [23, 25, 26]. It is thought that some of these patients
experience pain caused by medial tubal accumulation of blood
originating from residual cornual endometrium [23].
In our study, 79 % of women reported amenorrhea, 8 %
spotting, and 15 % hypomenorrhea. Of these, 96 % were satisfied and 99 % felt that it was worthwhile to have undergone
RHEA. Gimpleson and Kaigh reported that RHEA resulted in
amenorrhea in 10 women (63 %), staining in 3 (19 %), and
light flow in 3 (19 %) [13], while Wortman and Daggett reported that 88.5 % achieved satisfactory results and avoided
hysterectomy [12].
We did not use any pretreatment to thin the endometrium
prior to RHEA believing that identification of residual endometrium may be more difficult. In fact, Hansen et al. reported
that pretreatment increased the risk of subsequent hysterectomy (81 vs 30 %, p>0.01) possibly due to difficulties in
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identifying endometrial mucosa, in these scarred and distorted
uterine cavities, when pretreatment is used [15].
Additional strategies to increase efficacy of primary endometrial ablation have included better patient [27] selection
and/or endometrial ablation technology [28]. However, the
long-term clinical outcomes (up to 10 years) are similar
among all endometrial ablation technologies [6] and no significant differences in effectiveness or safety have been found
between first- and second-generation endometrial ablation
techniques [29, 30].
A final strategy may be to combine endometrial ablation
with adjunct therapy.
Indeed, preliminary studies indicate that the combination of
both HEA and non-HEA with DMPA [31, 32] or the levonorgestrel intrauterine system (LNG-IUS) [33–36] significantly improve short-term clinical outcomes in women with AUB as determined by amenorrhea, satisfaction, and reintervention rates.
This study is of clinical significance since it highlights
several issues including feasibility, safety, and long-term effectiveness of repeat endometrial ablation. Strengths of the
study include the largest number of patients treated by both
primary and RHEA and the longest follow-up reported to date
while weaknesses include the retrospective nature and reflection of only one surgeon’s experience.
In summary, we have shown that RHEA is a feasible, relatively safe, and a long-term effective alternative to hysterectomy for AUB from benign causes when performed by experienced surgeons. However, two observations must be pointed
out regarding RHEA.
The first observation is that all authors have reported on
using the resectoscope to perform repeat ablations rather than
any of the nonhysteroscopic technologies. This, together with
the fact that the majority of endometrial cavities after primary
ablation by all methods is significantly distorted [37, 38], indicates that repeat ablation may not be feasible and possibly
dangerous, when attempted/performed by any technique other
than the hysteroscopic approach.
The second observation is that RHEA has been reported
mostly by some of the pioneers and expert surgeons on the use
of resectoscopic surgery including HEA [12–16]. However,
since presently, HEA has been mostly substituted by nonHEA techniques [39, 40], the art of HEA may be on its way
to extinction. Consequently, the more technically difficult and
skill-demanding RHEA will remain in the domain of a handful
of surgeons and not an option provided by the majority of
gynecologists.
Conflict of interest The authors declare that they have no competing
interests.
Precis Repeat hysteroscopic endometrial ablation is a feasible, safe,
and long-term effective alternative to hysterectomy for benign abnormal
uterine bleeding when performed by experienced surgeons.
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